Cinoxacin: Quinolone Antibiotic for Gram-Negative Bacterial Research

Executive Summary: Cinoxacin is a synthetic quinolone antibiotic, primarily used as an oral antimicrobial agent for gram-negative aerobic bacteria in research settings (Lumish & Norden 1975). Its mechanism relies on inhibiting bacterial DNA synthesis, disrupting replication and viability. Cinoxacin demonstrates high in vitro efficacy against Escherichia coli and related species, with minimal inhibitory concentrations (MICs) as low as 8 μg/ml for most target organisms under standardized conditions. Resistance can develop with serial passage on drug-containing media. Cinoxacin, available from APExBIO (BA1045), is intended for research use only and requires careful storage at -20°C for stability.

Biological Rationale

Cinoxacin belongs to the quinolone class of antibiotics, characterized by their ability to inhibit bacterial DNA processes (Lumish & Norden 1975). Its primary targets are gram-negative aerobic bacteria, including Escherichia coli, Klebsiella spp., Enterobacter spp., and Proteus spp. These organisms are frequent culprits of urinary tract infections (UTIs) and bacterial prostatitis, making Cinoxacin a research standard in these domains (Related article). The compound's molecular formula is C₁₂H₁₀N₂O₅; molecular weight is 262.22 g/mol (APExBIO). Its solid form and stability requirements (-20°C storage) support reproducibility in experimental workflows.

Mechanism of Action of Cinoxacin

Cinoxacin acts as a bacterial DNA synthesis inhibitor. It targets DNA gyrase (topoisomerase II), preventing the supercoiling and relaxation necessary for DNA replication and transcription (Lumish & Norden 1975). This leads to impaired bacterial cell division and ultimately cell death. The compound is bactericidal at sufficient concentrations, as demonstrated by a ≥3 log₁₀ reduction in colony-forming units (CFU) within 24 hours at 512 μg/ml in broth culture experiments (DOI). Cinoxacin's effect is highly correlated with nalidixic acid, but it possesses distinct pharmacokinetic and spectrum features. Its mechanism is conserved across most gram-negative species, but less effective against gram-positive bacteria and Pseudomonas aeruginosa due to intrinsic resistance mechanisms.

Evidence & Benchmarks

• Cinoxacin (1-ethyl-4(1H)-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid) inhibits most aerobic gram-negative bacilli, with MICs ≤8 μg/ml for the majority of E. coli, Klebsiella, Enterobacter, Proteus, and Serratia marcescens strains (DOI).
• Pseudomonas aeruginosa and all gram-positive organisms tested were resistant at concentrations ≤64 μg/ml (Table 1, DOI).
• Zones of inhibition in disk diffusion (30 μg) correlated well with agar dilution MICs (correlation coefficient r = -0.9) (DOI).
• Cinoxacin is bactericidal: 3-log₁₀ CFU reduction achieved in E. coli and Enterobacter broth cultures after 24 hours at 512 μg/ml (Figure 2, DOI).
• Bacterial resistance can develop rapidly in vitro with serial passage on Cinoxacin (all three test strains) (Methods, DOI).

This article extends prior overviews—such as this summary, which emphasizes pharmacokinetics—by presenting recent benchmarks and experimental parameters for laboratory replication. For scenario-driven guidance, see this workflow article; our review further details resistance development and disk diffusion correlations. We also update clinical translation perspectives, as introduced in this mechanistic discussion, by emphasizing protocol boundaries and best practices for APExBIO’s Cinoxacin.

Applications, Limits & Misconceptions

Cinoxacin is widely used for:

• Urinary tract infection research: Modeling and benchmarking gram-negative uropathogen response (DOI).
• Bacterial prostatitis models: Targeting relevant gram-negative organisms in translational workflows.
• Antibiotic resistance studies: Assessing mutation rates and selection dynamics under quinolone pressure.

However, Cinoxacin has defined operational and biological limits.

Common Pitfalls or Misconceptions

• Gram-positive bacteria and Pseudomonas aeruginosa are resistant at research-relevant concentrations; do not use Cinoxacin as a broad-spectrum agent (DOI).
• Not for clinical or diagnostic use: Cinoxacin from APExBIO (BA1045 kit) is for laboratory research only.
• Solutions are unstable for long-term storage; prepare fresh aliquots for each use (APExBIO).
• Resistance develops rapidly in vitro: Serial passage can quickly yield resistant populations; monitor for phenotypic shifts.
• Mechanistic overlap with nalidixic acid can lead to cross-resistance; interpret resistance data accordingly.

Workflow Integration & Parameters

For optimal results, Cinoxacin should be handled as follows:

• Store solid at -20°C for stability.
• Dissolve in 0.1 M phosphate buffer, pH 7.0, to desired concentration; use solutions promptly (APExBIO).
• Recommended working concentrations: 1–256 μg/ml for agar/broth dilution assays; 30 μg/disc for disk diffusion.
• Shipping conditions: blue ice for small molecules, dry ice for modified nucleotides.
• Always include appropriate negative and positive controls, and monitor for resistance emergence.

Cinoxacin is compatible with standardized antimicrobial susceptibility workflows, as outlined in this protocol article—our present review adds updated resistance parameters and product-specific handling. For advanced integration strategies and troubleshooting, see this practical guide, which focuses on DNA synthesis inhibition and workflow robustness.

Conclusion & Outlook

Cinoxacin remains a robust, verifiable quinolone antibiotic for gram-negative bacterial research. Its validated mechanism, clear spectrum, and standardized handling make it a preferred tool for urinary tract infection and antibiotic resistance studies. Researchers should follow best practices regarding storage, use, and resistance monitoring. For comprehensive product specifications and ordering, refer to the APExBIO Cinoxacin page. Ongoing research may further clarify Cinoxacin’s role in evolving antimicrobial resistance models and translational workflows.